A small-molecule inhibitor of the Wnt pathway, lorecivivint (SM04690), as a potential disease-modifying agent for the treatment of degenerative disc disease.

Deshmukh, Vishal; Ibanez, Maureen; Hu, Haide; Cahiwat, Joseph; Wei, Ying; Stewart, Joshua; Hood, John; Yazici, Yusuf

Deshmukh, Vishal; Ibanez, Maureen; Hu, Haide; Cahiwat, Joseph; Wei, Ying; Stewart, Joshua; Hood, John; Yazici, Yusuf.

Affiliation

Deshmukh V; Samumed, LLC, San Diego, CA, USA. Electronic address: vishal@samumed.com.
Ibanez M; Samumed, LLC, San Diego, CA, USA.
Hu H; Formerly Samumed, LLC, San Diego, CA, USA.
Cahiwat J; Samumed, LLC, San Diego, CA, USA.
Wei Y; Formerly Samumed, LLC, San Diego, CA, USA.
Stewart J; Samumed, LLC, San Diego, CA, USA.
Hood J; Formerly Samumed, LLC, San Diego, CA, USA.
Yazici Y; Samumed, LLC, San Diego, CA, USA.

Spine J ; 20(9): 1492-1502, 2020 09.

Article in En | MEDLINE | ID: mdl-32413487

Subject(s)

Intervertebral Disc Degeneration; Intervertebral Disc; Animals; Imidazoles; Indazoles; Intervertebral Disc Degeneration/drug therapy; Pyridines; Rats; Wnt Signaling Pathway

Key words

Degenerative disc disease; Disease modification; Lorecivivint; NP cells; Small molecule; Wnt signaling

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Intervertebral Disc Degeneration / Intervertebral Disc Limits: Animals Language: En Journal: Spine J Journal subject: ORTOPEDIA Year: 2020 Document type: Article Country of publication: United States

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google